Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D.GlobeNewsWire • 10/25/22
Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast CancerGlobeNewsWire • 10/24/22
Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 09/07/22
Registration Now Open for Tribe Public's Webinar Event "The Important Role For Inhalation Therapy In Oncology" Featuring The Management Team From Atossa Therapeutics on August 25, 2022GlobeNewsWire • 08/22/22
Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory BoardGlobeNewsWire • 08/18/22
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/08/22
Dosing Completed in Part C of Atossa's Phase 1/2a Study of AT-H201 in Healthy VolunteersGlobeNewsWire • 07/28/22
Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public RelationsGlobeNewsWire • 06/02/22
Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment ConferenceGlobeNewsWire • 05/18/22
Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201GlobeNewsWire • 04/20/22
Atossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth ConferenceGlobeNewsWire • 03/23/22
Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/28/22
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022GlobeNewsWire • 01/27/22
Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201GlobeNewsWire • 01/18/22
Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in SwedenGlobeNewsWire • 12/22/21
Physician-Scientist Steven Quay Calls for International Effort to Investigate a Coronavirus discovered in Laos by Institut PasteurPRNewsWire • 12/16/21
Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug AdministrationGlobeNewsWire • 12/06/21